お問い合わせ
アクセス

研究業績

ACHIEVEMENT


代謝内科学業績

業績 – 論文

2022年

  • Yoshizawa T, Sato Y, Sobuz SU, Mizumoto T, Tsuyama T, Karim MF, Miyata K, Tasaki M, Yamazaki M, Kariba Y, Araki N, Araki E, Kajimura S, Oike Y, Braun T, Bober E, Auwerx J, Yamagata K. SIRT7 suppresses energy expenditure and thermogenesis by regulating brown adipose tissue functions in mice. Nature Communications 13(1):7439.
  • Araki H, Matsumura T, Furukawa N, Araki E. Updates of incretin-related drugs for the treatment of type 2 diabetes. Journal of Diabetes Investigation. 14(2):189-192.
  • Sakaguchi M, Okagawa S, Okubo Y, Otsuka Y, Fukuda K, Igata M, Kondo T, Sato Y, Yoshizawa T, Fukuda T, Yamagata K, Cai W, Tseng YH, Sakaguchi N, Kahn CR, Araki E. Phosphatase Protector Alpha4 (α4) is involved in Adipocyte Maintenance and Mitochondrial Homeostasis through Regulation of Insulin Signaling. Nature Communications 13(1):6092, 2022.
  • Araki E, Harashima S, Nishida T, Nakamura J: Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis. Journal of Diabetes Investigation 13(12):1971-1980,
  • Araki E, Sakaguchi M, Fukuda K, Kondo T: Potential of a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes. Journal of Diabetes Investigation 13(12):1958-1960,
  • Saishouji F, Maeda S, Hamada H, Kimura N, Tamanoi A, Nishida S, Sakaguchi M, Igata M, Yokoo K, Kawakami F, Araki E, Kondo T. Ectopic ACTH-producing neuroendocrine tumor occurring with large recurrent metastatic pheochromocytoma: a case report. BMC Endocrine Disorders22(1):184, 2022.
  • Matsumura T, Makabe T, Ueda S, Fujimoto Y, Sadahiro K, Tsuruyama S, Ookubo Y, Kondo T, Araki E. Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes.Diabetes Therapy 13(9):1621-1634, 2022.
  • Horikawa C, Tsuda K, Oshida Y, Satoh J, Hayashino Y, Tajima N, Nishimura R, Sone H, JDCP Study Group (Araki E. et al.). Dietary intake and physical activity in Japanese patients with type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 8). Diabetology International 13(2):344-357, 2022.
  • Naito H, Sueta D, Hanatani S, Ikeda H, Hirosue A, Senokuchi T, Araki E, Tsujita K, Nakayama H, Kasaoka S. Factors Affecting Human Damage in Heavy Rains and Typhoon Disasters.
    The Tohoku Journal of Experimental Medicine 256(2):175-185, 2022.
  • Ogawa W, Araki E, Ishigaki Y, Hirota Y, Maegawa H, Yamauchi T, Yorifuji T, Katagiri H. New classification and diagnostic criteria for insulin resistance syndrome. Endocrine Journal 69(2):107-113, 2022.
  • Ogawa W, Araki E, Ishigaki Y, Hirota Y, Maegawa H, Yamauchi T, Yorifuji T, Katagiri H. New classification and diagnostic criteria for insulin resistance syndrome. Diabetology Intl 13:337-343, 2022.
  • Ikeda T, Ishihara A, Mitsumasu S, Yamanouchi Y, Kanemaru H, Sakakida K, Morinaga J, Araki E. Questionnaire Survey Regarding Troubles and Concerns Related to Clinical Research Based on the Clinical Trial Act for Clinicians and Academics. The Kurume Medical Journal 67(1):17-21, 2022.
  • Araki H, Hino S, Anan K, Kuribayashi K, Etoh K, Seko D, Takase R, Kohrogi K, Hino Y, Ono Y, Araki E, Nakao LSD1 defines the fiber type-selective responsiveness to environmental stress in skeletal muscle. eLife 12: e84618, 2023.
  • Thamrongwaranggoon U, Kuribayashi K, Araki H, Hino Y, Koga T, Seubwai W, Wongkham S, Nakao M, Hino S. Lactic acidosis induces metabolic and phenotypic reprogramming in cholangiocarcinoma cells via the upregulation of thrombospondin-1. Cancer Sci. 2022 Dec 23.
  • Shoji T, Akiyama Y, Fujii H, Harada-Shiba M, Ishibashi Y, Ishida T, Ishigaki Y, Kabata D, Kihara Y, Kotani K, Kurisu S, Masuda D, Matoba T, Matsuki K, Matsumura T, Mori K, Nakagami T, Nakazato M, Taniuchi S, Ueno H, Yamashita S, Yoshida H, Yoshida H. Association of Kidney Function with Serum Levels of Cholesterol Absorption and Synthesis Markers: The CACHE Study CKD Analysis. J Atheroscler Thromb 29(12):1835-1848, 2022.
  • Matsumura T, Ishigaki Y, Nakagami T, Akiyama Y, Ishibashi Y, Ishida T, Fujii H, Harada-Shiba M, Kabata D, Kihara Y, Kotani K, Kurisu S, Masuda D, Matoba T, Matsuki K, Mori K, Nakazato M, Taniuchi S, Ueno H, Yamashita S, Yoshida H, Yoshida H, Shoji T. Relationship between Diabetes Mellitus and Serum Lathosterol and Campesterol Levels: The CACHE Study DM Analysis. J Atheroscler Thromb, In press.
  • Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med 387(21):1923-1934, 2022.
  • Ishibashi Y, Yoshida H, Kotani K, Akiyama Y, Fujii H, Harada-Shiba M, Ishida T, Ishigaki Y, Kabata D, Kihara Y, Kurisu S, Masuda D, Matoba T, Matsuki K, Matsumura T, Mori K, Nakagami T, Nakazato M, Taniuchi S, Ueno H, Yamashita S, Yano S, Yoshida H, Tetsuo S. Serum Values of Cholesterol Absorption and Synthesis Biomarkers in Japanese Healthy Subjects: The CACHE Study HEALTHY Analysis. J Atheroscler Thromb, In press.
  • Matsuki K, Harada-Shiba M, Hori M, Ogura M, Akiyama Y, Fujii H, Ishibashi Y, Ishida T, Ishigaki Y, Kabata D, Kihara Y, Kotani K, Kurisu S, Masuda D, Matoba T, Matsumura T, Mori K, Nakagami T, Nakazato M, Taniuchi S, Ueno H, Yamashita S, Yoshida H, Yoshida H, Shoji T. Association between Familial Hypercholesterolemia and Serum Levels of Cholesterol Synthesis and Absorption Markers: The CACHE Study FH Analysis. J Atheroscler Thromb, In press.
  • Matsushima-Nagata K, Matsumura T, Kondo Y, Anraku K, Fukuda K, Yamanaka M, Manabe M, Irie T, Araki E, Sugiuchi H. Relationship between remnant circulating lipoprotein choles-terol concentration, measured by homogeneous assay, and clinical parameters in patients with type 2 diabetes. Biomolecules, In press.

2021年

  • Igata M, Yagi Y, Hanatani S, Sakaguchi M, Ishii N, Yoshinaga K, Kawashima J, Motoshima H, Araki E. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma. J Diabetes Investig. 12(4):668-671. 2021
  • Matsushima-Nagata K, Sugiuchi H, Anraku K, Takao T, Kondo Y, Ishitsuka Y, Irikura M, Irie T, Matsumura T,Araki E, Sumida M, Katayama Y, Kayahara N. A homogeneous assay to determine high-density lipoprotein subclass cholesterol in serum. Anal Biochem 613:114019. 2021.
  • Nishikawa T,Kinoshita H, Ono K, Hashimoto S, Kobayashi Y, Nakamura T, Yoshinaga T, Ohkubo Y, Harada M, Toyonaga T, Takahashi T, Araki Clinical profiles of hyperglycemic crises: A single‐center retrospective study from Japan. J Diabetes Investig 12(8):1359-1366. 2021.
  • Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y,Araki E, Yamazaki T, Kadowaki T; J-BRAND Registry Group. Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational  BMJ Open Diab Res & Care 9(1): e001787. 2021.
  • Nakamaru R, Yamamoto K, Akasaka H, Rakugi H, Kurihara I, Yoneda T, Ichijo T, Katabami T, Tsuiki M, Wada N, Yamada T, Kobayashi H, Tamura K, Ogawa Y, Kawashima J, Inagaki N, Fujita M, Oki K, Kamemura K, Tanabe A, Naruse M; JPAS/JRAS study group. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism. Hypertension 77(2):537-545, 2021
  • Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Hepatocellular Carcinoma Development in Diabetic Patients: A Nationwide Survey in Japan J Gastroenterol 56(3):261-273. 2021.
  • Okawa ER, Gupta MK, Kahraman S, Goli P, Sakaguchi M, Hu J, Duan K, Slipp B, Lennerz JK, Kulkarni RN. Essential roles of insulin and IGF-1 receptors during embryonic lineage development. Mol Metab 47:101164.
  • Yamashita S, Okazaki M, Okada T, Masuda D, Yokote K, Arai H,Araki E, Ishibashi S. Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate. J Atheroscler Thromb 28(9):974-996. 2021.
  • Araki E, Mathieu C, Shiraiwa T, Maeda H, Ikeda H, Thoren F, Arya N, Asano M, Iqbal N. Long-term (52-week) efficacy and safety of dapagliflozin as adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study. Diabetes Obes Metab 23(7):1496-1504. 2021.
  • Kondo T, Kitano S, Miyakawa N, Watanabe T, Goto R, Sato M, Hanatani S, Sakaguchi M, Igata M, Kawashima J, Motoshima H, Matsumura T, Araki E. The Amount of Residual Incretin Regulates the Pancreatic β-cell Function and Glucose Homeostasis. Intern Med. 60(9):1433-1442. 2021.
  • Yokote K, Yamashita S, Arai H,Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. Cardiovasc Diabetol. 20(1):96. 2021.
  • Kondo T, Miyakawa N, Kitano S, Watanabe T, Goto R, Suico MA, Sato M, Takaki Y, Sakaguchi M, Igata M, Kawashima J, Motoshima H, Matsumura T, Kai H,Araki E. Activation of heat shock response improves biomarkers of NAFLD in patients with metabolic diseases. Endocr Connect. 10(5):521-533. 2021.
  • Araki E, Terauchi Y, Watada H, Deenadayalan S, Christiansen E, Horio H, Kadowaki T. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials. Diabetes Obes Metab 23(12):2785-2794. 2021.
  • Phillip M, Mathieu C, Lind M, Araki E, di Bartolo P, Bergenstal R, Heller S, Hansen L, Scheerer MF, Thoren F, Arya N, Xu J, Iqbal N, Dandona P. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.Diab, Obesity & Metab. 23(2): 549-560, 2021.
  • Kohrogi K, Hino S, Sakamoto A, Anan K, Takase R, Araki H, Hino Y, Araki K, Sato T, Nakamura K, Nakao M. LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα. Blood Adv. 5(9): 2305-2318, 2021.
  • Ogawa W, Araki E, Ishigaki Y, Hirota Y, Maegawa H, Yamauchi T, Yorifuji T, Katagiri H. New classification and diagnostic criteria for insulin resistance syndrome. Endocrine Journal. 69(2): 175-185, 2022.
  • Naito H, Sueta D, Hanatani S, Ikeda H, Hirosue A, Senokuchi T,Araki E, Tsujita K, Nakayama H, Kasaoka S. Factors Affecting Human Damage in Heavy Rains and Typhoon Disasters. Tohoku J Exp Med. 256(2):175-185, 2022.
  • Ogawa W, Araki E, Ishigaki Y, Hirota Y, Maegawa H, Yamauchi T, Yorifuji T, Katagiri H. New classification and diagnostic criteria for insulin resistance syndrome. Diabetol Int. 2022, in press.
  • Ikeda T, Ishihara S, Mitsumasu S, Yamanouchi Y, Kanemaru H, Sakakida K, Morinaga J,Araki E. Questionnaire Survey Regarding Troubles and Concerns Related to Clinical Research Based on the Clinical Trial Act for Clinicians and Academics. Kurume Med J. 2022, in press.
  • Kawano T, Shinojima N, Hanatani S,Araki E, Mikami Y, Mukasa A. Atypical pituitary abscess lacking rim enhancement and diffusion restriction with an unusual organism, Moraxella catarrhalis: A case report and review of the literature. Surg Neurol Int. 2022, in press.
  • Shoji T, Akiyama Y, Fujii H, Harada-Shiba M, Ishibashi Y, Ishida T, Ishigaki Y, Kabata D, Kihara Y, Kotani K, Kurisu S, Masuda D, Matoba T, Matsuki K, Matsumura T, Mori K, Nakagami T, Nakazato M, Taniuchi S, Ueno H, Yamashita S, Yoshida H, Yoshida H. Association of Kidney Function with Serum Levels of Cholesterol Absorption and Synthesis Markers: The CACHE Study CKD Analysis. J Atheroscler Thromb. 2022, in press.

2020年

  • Komorita T, Fujisue K, Sueta D, Sakamoto K, Yamamoto E, Hashimoto Y, Sakamoto T, Tsunoda R, Uesugi H, Suzuki R, Naito H, Hanzawa K, Araki E, Nakayama H, Kasaoka S, Hokimoto S, Fukui T, Tsujita K. Clinical Features of Patients with Acute Aortic Dissection After an Earthquake ～Experience from The Kumamoto Earthquake 2016~. Am J Hypertens 33(3):261-268, 2020.
  • Araki E, Watada H, Uchigata Y, Tomonaga O, Fujii H, Ohashi H, Okabe T, Asano M, Thoren F, Kim H, Yajima T, Langkilde AM. Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial. Diab, Obesity & Metab　22(4):540-548, 2020.
  • Nishida S, Matsumura T, Senokuchi T, Murakami-Nishida S, Ishii N, Morita Y, Yagi Y, Motoshima H, Kondo T, Araki E. Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions. Biochem Biophys Res Commun 524(1):8-15, 2020.

2019年

  • Watada H, Shiramoto M, Ueda S, Tang W, Asano M, Thoren F, Kim H, Yajima T, Boulton DW, Araki E: Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Combination with Insulin in Japanese Patients with Type 1 Diabetes. Diab, Obesity & Metab 21:876-882, 2019.
  • Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S and on Behalf of the K-877 Study Group. Long-Term Efficacy and Safety of Pemafibrate,a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment. Int J Molec Sci 20(3). pii: E706, 2019.
  • Kondo T, Nakamura M, Kawashima J, Matsumura T, Ohba T, Yamaguchi M, Katabuchi H, Araki E. Hyperemesis gravidarum followed by refeeding syndrome causes electrolyte abnormalities induced rhabdomyolysis and diabetes insipidus. Endocr J 28;66(3):253-258, 2019.
  • Kitano S, Kondo T, Matsuyama R, Ono K, Goto R, Takaki Y, Hanatani S, Sakaguchi M, Igata M, Kawashima J, Motoshima H, Matsumura T, Kai H, Araki E. Impact of hepatic HSP72 on insulin signaling. Am J Physiol Endocrinol Metab 316(2): E305-E318 2019.
  • Takahashi H, Alves C, Stanford K, Middelbeek R, Nigro P, Ryan R, Xue R, Sakaguchi M, Lynes M, So K, Mul J, Lee M. Y, Balan E, Pan H, Dreyfuss J, Hirshman M, Azhar M, Hannukainen J, Kalliokoski K, Nielsen S, Pedersen B, Kahn C.R, Tseng YH, Nuutila P, Goodyear L. TGF-β2 is an exercise-induced adipokine that regulates glucose and fatty acid metabolism. Nature Metab 1(2):291-303, 2019.
  • Ramirez AK, Dankel S, Cai W, Sakaguchi M, Kasif S, Kahn CR. Membrane metallo-endopeptidase (Neprilysin) regulates inflammatory response and insulin signaling in white preadipocytes. Mol Metab 22:21-36, 2019.
  • Batista TM, Cai W, Garcia-Martin R, Konishi M, O’Neill BT, Sakaguchi M, Jung DY, Kim JH, Kim JK, Kahn CR. Multi-level Transcriptional Remodeling by Insulin in Muscle and Liver in Vivo. Cell Reports 19;26(12):3429-3443.e3, 2019.
  • Sakaguchi M, Cai W, Wang CH, Cederquist CT, Damasio M, Homan EP, Batista T, Ramirez AK, Gupta MK, Steger M, Albrechtsen NJW, Singh SK, Araki E, Mann M, Enerbäck S, Kahn CR. FoxK1 and FoxK2 in Insulin Regulation of Cellular and Mitochondrial Metabolism. Nature Commun 10(1):1582, 2019.
  • Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S: The Efficacy and Safety of Pemafibrate in Patients with Type 2. Diabetes Obes Metab 21(7):1737-1744. 2019.
  • Takase R, Hino S, Nagaoka K, Anan K, Kohrogi K, Araki H, Hino Y, Sakamoto A, Nicholson T, Taiping Chen, and Nakao M. Lysine-specific demethylase-2 is distinctively involved in brown and beige adipogenic differentiation. FASEB J 33(4):5300-5311, 2019.
  • Goto R, Kondo T, Ono K, Kitano S, Miyakawa N, Watanabe T, Sakaguchi M, Sato M, Igata M, Kawashima J, Motoshima H, Matsumura T, Shimoda S, Araki E. Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets. J Clin Med 8(5):674, 2019.
  • Leiria LO, Wang CH, Lynes MD, Yang K, Shamsi F, Sato M, Sugimoto S, Chen EY, Bussberg V, Narain NR, Sansbury BE, Darcy J, Huang TL, Kodani SD, Sakaguchi M, Rocha AL, Schulz TJ, Bartelt A, Hotamisligil GS, Hirshman MF, van Leyen K, Goodyear LJ, Blüher M, Cypess AM, Kiebish MA, Spite M, Tseng YH. 12-Lipoxygenase Regulates Cold Adaptation and Glucose Metabolism by Producing the Omega-3 Lipid 12-HEPE from Brown Fat. Cell Metab S1550-4131(19)30374-2, 2019.
  • Murakami-Nishida S, Matsumura T, Senokuchi T, Ishii N, Kinoshita H, Yamada S, Morita Y, Nishida S, Motoshima H, Kondo T, Komohara Y, Araki E. Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ. Atherosclerosis 286:30-39, 2019.
  • Li ME, Lauritzen HPMM, O’Neill BT, Wang CH, Cai W, Brandao BB, Sakaguchi M, Tao R, Hirshman MF, Softic S, Kahn CR. Role of p110a subunit of PI3-kinase in skeletal muscle mitochondrial homeostasis and metabolism. Nature Commun 10(1):3412, 2019.
  • Shimoda S, Sakamoto W, Hokamura A, Matsuo Y, Sekigami T, Ichimori S, Iwashita S, Ishii N, Otsu K, Yoshimura R, Nishiyama T, Sakaguchi M, Nishida K, Araki E. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study. Endocr J EJ19-0179, 2019.
  • Langer J, Wolden ML, Shimoda S, Sato M, Araki E. Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy. Diabetes Ther 10(4):1347-1356, 2019.
  • Kaku K, Araki E, Tanizawa Y, Ross Agner B, Nishida T, Ranthe M, Inagaki N. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial. Diabetes Obes Metab 21(12):2674-2683, 2019.
  • Kondo T, Miyakawa N, Motoshima H, Hanatani S, Ishii N, Igata M, Yoshinaga K, Kukidome D, Senokuchi T, Kawashima J, Furukawa N, Matsumura T, Araki E. Impacts of the 2016 Kumamoto Earthquake on glycemic control in patients with diabetes. J Diabetes Investig 10(2):521-530, 2019.
  • Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, Takeda Y, Yoneda T, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ashida K, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Hashimoto S, Yamada M, Yoshikawa Y, Kai T, Suzuki T, Kawamura T, Naruse M, Japan Primary Aldosteronism Study Group. High Prevalence of Diabetes in Patients with Primary Aldosteronism (PA) associated with Subclinical Hypercortisolism and Prediabetes More Prevalent in Bilateral Than Unilateral PA: A Large, Multicenter Cohort Study in Japan. Diabetes care 42(5):938-945, 2019.
  • Kawashima A, Sone M, Inagaki N, Takeda Y, Itoh H, Kurihara I, Umakoshi H, Ichijo T, Katabami T, Wada N, Ogawa Y, Kawashima J, Fujita M, Miyauchi S, Okamura S, Fukuoka T, Yanase T, Izawa S, Yoshikawa Y, Hashimoto S, Yamada M, Kai T, Suzuki T, Naruse M. Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism. Eur J Endocrinol Pii: EJE-19-0047.R2. doi: 10.1530/EJE-19-0047, 2019.
  • Wada N, Shibayama Y, Yoneda T, Katabami T, Kurihara I, Tsuiki M, Ichijo T, Ogawa Y, Kawashima J, Sone M, Yoshimoto T, Matsuda Y, Fujita M, Kobayashi H, Tamura K, Kamemura K, Otsuki M, Okamura S, Naruse M, JPAS/JRAS Study Group. Lateralizing Asymmetry of Adrenal Imaging and Adrenal Vein Sampling in Patients With Primary Aldosteronism. J Endocr Soc 3(7):1393-1402, 2019.
  • Katabami T, Fukuda H, Tsukiyama H, Tanaka Y, Takeda Y, Kurihara I, Ito H, Tsuiki M, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Yanase T, Suzuki T, Naruse M, JPAS/JRAS Study Group. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism. J Hypertens 37(7):1513-1520, 2019.
  • Nagasawa M, Yamamoto K, Rakugi H, Takeda M, Akasaka H, Umakoshi H, Tsuiki M, Takeda Y, Kurihara I, Itoh H, Ichijo T, Katabami T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Ogo A, Okamura S, Miyauchi S, Yanase T, Suzuki T, Kawamura T, Naruse M, JPAS Study Group. Influence of antihypertensive drugs in the subtype diagnosis of primary aldosteronism by adrenal venous sampling. J Hypertens 37(7):1493-1499, 2019.
  • Fujii Y, Takeda Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Yamamto K, Ogo A, Yanase T, Okamura S, Miyauchi S, Fujita M, Suzuki T, Umakoshi H, Ogasawara T, Tsuiki M, Naruse M, JPAS Study Group. Historical changes and between-facility differences in adrenal venous sampling for primary aldosteronism in Japan. J Hum Hypertens doi: 10.1038/s41371-019-0229-4, 2019.
  • Akasaka H, Yamamoto K, Rakugi H, Nagasawa M, Nakamaru R, Ichijo T, Takeda Y, Kurihara I, Katabami T, Tsuiki M, Wada N, Ogawa Y, Kawashima J, Sone M, Kamemura K, Yoshimoto T, Matsuda Y, Fujita M, Kobayashi H, Watanabe M, Tamura K, Okamura S, Miyauchi S, Izawa S, Chiba Y, Tanabe A, Naruse M, Japan Primary Aldosteronism Study Group*. Sex Difference in the Association Between Subtype Distribution and Age at Diagnosis in Patients with Primary Aldosteronism. Hypertens 74(2):368-374, 2019.
  • Kobayashi H, Abe M, Nakamura Y, Takahashi K, Fujita M, Takeda Y, Yoneda T, Kurihara I, Itoh H, Tsuiki M, Wada N, Ichijo T, Katabami T, Ogawa Y, Kawashima J, Yoshimoto T, Sone M, Inagaki N, Watanabe M, Kamemura K, Matsuda Y, Izawa S, Tanabe M, Tanabe A, Suzuki T, Naruse M, JPAS/JRAS Study Group. Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function. Hypertens 74(3):630-638, 2019.
  • Takeda Y, Umakoshi H, Takeda Y, Yoneda T, Kurihara I, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamto K, Ogo A, Yanase T, Suzuki T, Naruse M, JPAS Study Group. Impact of adrenocorticotropic hormone stimulation during adrenal venous sampling on outcomes of primary aldosteronism. J Hypertens 37(5):1077-1082, 2019.
  • Nakao M, Anan K, Araki H, Hino S. Distinct Roles of the NAD+-Sirt1 and FAD-LSD1 Pathways in Metabolic Response and Tissue Development. Trends Endocrinol Metab 30(7): 409-412, 2019.
  • Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E. Efficacy, Safety and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin ± Metformin in Patients with Type 2 Diabetes: The PIONEER 8 Trial. Diabetes care 42(12):2262-2271, 2019.
  • Sueta D, Tabata N, Ikeda S, Saito Y, Ozaki K, Sakata K, Matsumura T, Yamamoto-Ibusuki M, Murakami Y, Jodai T, Fukushima S, Yoshida N, Kamba T, Araki E, Iwase H, Fujii K, Ihn H, Kobayashi Y, Minamino T, Yamagishi M, Maemura K, Baba H, Matsui K, Tsujita K. Differential Predictive Factors for Cardiovascular Events in Patients with or without Cancer History. Medicine 98(44):e17602, 2019.
  • Araki E, Unno Y, Tanaka Y, Sakamoto W, Miyamoto Y. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial. Adv Ther 36 (10): 2697-2711, 2019.
  • Morisaki M, Kurihara I, Itoh H, Naruse M, Takeda Y, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Sone M, Tsuiki M, Shibata H, Kawashima J, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Suzuki T, JPAS Study Group. Predictors of Clinical Success After Surgery for Primary Aldosteronism in the Japanese Nationwide Cohort. J Endocr Soc 3: 2012-2022, 2019
  • Yamashita S, Arai H, Yokote K, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. Int J Mol Sci 20(22):5537, 2019.

2018年

  • Kondo T, Nakamura M, Kitano S, Kawashima J, Matsumura T, Ohba T, Yamaguchi M, Katabuchi H, Araki E: The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report. BMC Endocr Disord 18:4, 2018.
  • Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S; K-877 Study Group: Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol 12(1):173-184, 2018.
  • Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S: Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes Care 2018 41(3):538-546, 2018
  • Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Ichijo T, Katabami T, Tanaka Y, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Yoneda T, Hashimoto S, Yanase T, Suzuki T, Kawamura T, Tabara Y, Matsuda F, Naruse M; Nagahama Study; JPAS Study Group: Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan. Hypertension 71(3): 530-537, 2018.
  • Umakoshi H, Tsuiki M, Takeda Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamto K, Ogo A, Yanase T, Suzuki T, Naruse M; JPAS Study Group: Significance of Computed Tomography and Serum Potassium in Predicting Subtype Diagnosis of Primary Aldosteronism. J Clin Endocrinol Metab 103(3):900-908, 2018.
  • Ono K, Igata M, Kondo T, Kitano S, Takaki Y, Hanatani S, Sakaguchi M, Goto R, Senokuchi T, Kawashima J, Furukawa N, Motoshima H, Araki E: Identification of microRNA that represses IRS-1 expression in liver. PLoS One 13:e0191553, 2018.
  • Yamada S, Senokuchi T, Matsumura T, Morita Y, Ishii N, Fukuda K, Murakami S, Nishida S, Kawasaki S, Motoshima H, Furukawa N, Komohara Y, Fujiwara Y, Koga T, Yamagata K, Takeya M, Araki E: Inhibition of local macrophage growth ameliorates focal inflammation and suppresses atherosclerosis. Arterioscler Thromb Vasc Biol 38(5):994-1006, 2018.
  • Sakakida K, Wei FY, Senokuchi T, Shimoda S, Kakuma T, Araki E, Tomizawa K: The eperisone for diabetes with inpaired tRNA(EDIT) study group: Study desirn of a phase II clinical trial to assess the efficacy and safety of eperisone in Japanese type 2 diabetes patients with risk and non-risk alleles of CDKAL1. Acta Med Okayama 72(4):423-426, 2018.
  • Altindis E, Cai W, Sakaguchi M, Zhang F, Guoxiao W, Liu F, Meyts PD, Gelfanov V, Pan H, DiMarchi R, Kahn CR: Viral insulin-like peptides activate human insulin and IGF-1 receptor signaling: A new paradigm for host-microbe interactions. Proc Natl Acad Sci USA 115(10):2461-2466, 2018.
  • Umakoshi H, Ogasawara T, Takeda Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamto K, Ogo A, Yanase T, Okamura S, Miyauchi S, Suzuki T, Tsuiki M, Naruse M; JPAS Study Group: Accuracy of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of aldosterone in primary aldosteronism. Clin Endocrinol (Oxf) 88(5):645-651, 2018.
  • Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E: Japanese Clinical Practice Guideline for Diabetes 2016. J Diab Investig 9(3): 657–697, 2018
  • Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, Suganami H, Araki E: Effects of a novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate (K-877), on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. J Diab Investig 9(6):1323-1332, 2018.
  • Cai W, Xue C., Sakaguchi M., Konishi M., Shirazian A., Ferris H. A., Li M., Yu R., Kleinridders A., Pothos E. N., C. & Kahn C. R. Insulin regulates astrocyte gliotransmission and modulates behavior. J Clin Investig 128(7):2914-2926, 2018.
  • Inoue H, Shinojima N, Ueda R, Yano S, Yamamoto K, Ishii N, Igata M, Kawashima J, Araki E, Iwase H, Mikami Y, Mukasa A: A Rare Case of Thyrotropin-Secreting Pituitary Adenoma Coexisting with Papillary Thyroid Carcinoma Presenting with Visual Disturbance Without Hyperthyroidism. World Neurosurg S1878-8750(18)31754-6, 2018.
  • Anan K, Hino S, Arai H, Shimizu N, Sakamoto A, Nagaoka K, Takase R, Kohrogi K, Araki H, Usuki S, Oki S, Tanaka H, Nakamura K, Endo F, Nakao M: LSD1 mediates metabolic reprogramming by glucocorticoid during myogenic differentiation. Nucleic Acids Res 46(11):5441-5454, 2018.
  • Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group.: Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. J Atheroscler & Thromb 25(6):521-538, 2018.
  • Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, Araki E, Chu PL, Wijayasinghe N, Norwood P: Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomised, controlled trial. J Clinic Endocrinol & Metab 103(6):2291-2301, 2018.
  • Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, Lind M, Bain SC, Jabbour S, Arya N, Hansen L, Thorén F, Langkilde AM, DEPICT-2 Investigators: Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes care 41(9):1938-1946, 2018.
  • Araki E, Senokuchi T, Furukawa N: Impacts of tight multifactorial intervention in patients with type 2 diabetes: Implications from J-DOIT3. J Diab Investig 9(5): 1022–1024, 2018.
  • Yamashita S, Arai H, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group: Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. J Clin Lipidol 12(5):1267-1279.e4, 2018.
  • Nishikawa T, Ono K, Hashimoto S, Kinoshita H, Watanabe T, Araki H, Otsu K, Sakamoto W, Harada M, Toyonaga T, Kawakami S, Fukuda J, Haga Y, Kukidome D, Takahashi T, Araki E: One-hour oral glucose tolerance test plasma glucose at gestational diabetes diagnosis is a common predictor of the need for insulin therapy in pregnancy and postpartum impaired glucose tolerance. J Diab Investig 9(6):1370-1377, 2018.
  • Kondo T, Miyakawa N, Motoshima H, Hanatani S, Ishii N, Igata M, Yoshinaga K, Kukidome D, Senokuchi T, Kawashima J, Furukawa N, Matsumura T, Araki E: Impacts of the 2016 Kumamoto Earthquake on glycemic control in patients with diabetes. J Diab Investig 10(2):521-530, 2018.
  • Takeda M, Yamamoto K, Akasaka H, Rakugi H, Naruse M, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Ichijo T, Katabami T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Ogo A, Okamura S, Miyauchi S, Yanase T, Suzuki T, Kawamura T; JPAS Study Group: Clinical characteristics and postoperative outcomes of primary aldosteronism in the elderly. J Clin Endocrinol & Metab 103(10):3620-3629. 2018.
  • Umakoshi H, Tsuiki M, Yokomoto-Umakoshi M, Takeda Y, Takashi Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ashida K, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Yanase T, Hashimoto S, Yamada M, Yoshikawa Y, Kai T, Suzuki T, Kawamura T, Naruse M: Correlation Between Lateralization Index of Adrenal Venous Sampling and Standardized Outcome in Primary Aldosteronism. J Endocr Soc 2(8):893-902, 2018.
  • Kobayashi H, Abe M, Soma M, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Shibata H, Kamemura K, Yanase T, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Nanba K, Tanabe A, Suzuki T, Naruse M; JPAS Study Group: Development and validation of subtype prediction scores for the workup of primary aldosteronism. J Hypertens 36(11):2269-2276, 2018.
  • Takeda Y, Umakoshi H, Takeda Y, Yoneda T, Kurihara I, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamto K, Ogo A, Yanase T, Suzuki T, Naruse M; JPAS Study Group: Impact of adrenocorticotropic hormone stimulation during adrenal venous sampling on outcomes of primary aldosteronism. J Hypertens. 37(5):1077-1082. 2018.
  • Shibayama Y, Wada N, Naruse M, Kurihara I, Ito H, Yoneda T, Takeda Y, Umakoshi H, Tsuiki M, Ichijo T, Fukuda H, Katabami T, Yoshimoto T, Ogawa Y, Kawashima J, Ohno Y, Sone M, Fujita M, Takahashi K, Shibata H, Kamemura K, Fujii Y, Yamamoto K, Suzuki T. The Occurrence of Apparent Bilateral Aldosterone Suppression in Adrenal Vein Sampling for Primary Aldosteronism. J Endocr Soc 2(5):398-407 2018.
  • Arai H Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group.: Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. J Atheroscler & Thromb 25(6):521-538, 2018.

2017年

  • Araki E, Onishi Y, Asano M, Kim H, Yajima T: Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: DAISY trial. Diabetes Obes Metab 19:562-570, 2017.
  • Araki E, Haneda M, Kasuga M, Nishikawa T, Kondo T, Ueki K, Kadowaki T: New glysemic targets for patients with diabetes from the Japan Diabetes Society. J Diabetes Investig 8(1):123-125, 2017.
  • Sakaguchi M, Fujisaka S, Cai W, Winnay JN, Konishi M, O’Neill BT, Li M, García-Martín R, Takahashi H, Hu J, Kulkarni RN, KahnCR: Adipocyte Dynamics and Reversible Metabolic Syndrome in Mice with an Inducible Adipocyte-Specific Deletion of the Insulin Receptor. Cell Metab 25(2):448-462, 2017.
  • Thomou T, Mori MA, Dreyfuss JM, Konishi M, Sakaguchi M, Wolfrum C, Rao TN, Winnay JN, Garcia-Martin R, Grinspoon SK, Gorden P, Kahn CR: Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature 542:450-455, 2017.
  • Cai W, Sakaguchi M, Kleinridders A, Gonzalez-Del Pino G, Dreyfuss JM, O’Neill BT, Ramirez AK, Pan H, Winnay JN, Boucher J, Eck MJ, Kahn CR: Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression. Nat Commun 8:14892, 2017.
  • Konishi M, Sakaguchi M, Lockhart SM, Cai W, Li ME, Homan EP, Rask-Madsen C, Kahn CR: Endothelial insulin receptors differentially control insulin signaling kinetics in peripheral tissues and brain of mice. Proc Natl Acad Sci USA 114(40):E8478-E8487, 2017.
  • Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, on behalf of the K-877 Study Group: Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis 261:144-152, 2017.
  • Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, Ueki K, Nakayama T: Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 8(3):397-410, 2017.
  • Kajihara N, Kukidome D, Sada K, Motoshima H, Furukawa N, Matsumura T, Nishikawa T, Araki E: Low glucose induces mitochondrial reactive oxygen species via fatty acid oxidation in bovine aortic endothelial cells. J Diabetes Investig 8:750-761, 2017.
  • Matsumura T, Yamamoto E, Tsujita K, Araki E: Potential of Monocyte Count for the Assessment of Cardiovascular Disease. Cardiovasc Pharmacol 6:217, 2017.
  • Kukidome D, Nishikawa T, Sato M, Nishi Y, Shimamura R, Kawashima J, Shimoda S, Mizuta H, Araki E: Impaired balance is related to the progression of diabetic complications in both young and older adults. J diabetes complications 31(8):1275-1282, 2017.
  • Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T, J-DOIT3 Study Group.: Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 5(12): 951-964, 2017.
  • Yano S, Shinojima N, Kawashima J, Kondo T, Hide T: Intraoperative Scoring System to Predict Postoperative Remission in Endoscopic Endonasal Transsphenoidal Surgery for Growth Hormone-Secreting Pituitary Adenomas. World neurosurg 105:375-385, 2017.

2016年

  • Yamanaka M, Matsumura T, Ohno R, Fujiwara Y, Shinagawa M, Sugawa H, Hatano K, Shirakawa J, Kinoshita H, Ito K, Sakata N, Araki E, Nagai R: Non-invasive measurement of skin autofluorescence to evaluate diabetic complications. J Clin Biochem Nutr 58:135-140, 2016.
  • Fujisaka S, Ussar S, Clish C, Devkota S, Dreyfuss JM, Sakaguchi M, Soto M, Konishi M, Softic S, Altindis E, Li N, Gerber G, Bry L, Kahn CR: Antibiotic effects on gut microbiota and metabolism are host dependent. J Clin Invest 126(12):4430-4443, 2016.
  • Winnay JN, Solheim MH, Dirice E, Sakaguchi M, Noh HL, Kang HJ, Takahashi H, Chudasama KK, Kim JK, Molven A, Kahn CR, Njølstad PR: PI3-kinase mutation linked to insulin and growth factor resistance in vivo. J Clin Invest 126(4):1401-1412, 2016.
  • Araki E, Onishi Y, Kim H, Ekholm K, Jhonsson E, Yajima T: Efficacy and safety of dapaglifrozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blinded treatment period. J Diabetes Invest 2016, in press.
  • Igata M, Tsuruzoe K, Kawashima J, Kukidome D, Kondo T, Motoshima H, Shimoda S, Furukawa N, Nishikawa T, Miyamura N, Araki E: Coexistence of resistance to thyroid hormone (RTHβ) and papillary thyroid carcinoma. Endocrinology, Diabetes & Metabolism 2016:16-0003, 2016.
  • Shimoda S, Sato M, Sekigami T, Motoshima H, Yoshimura R, Fukuda K, Matsuo Y, Noda H, Okubo M, Ichimori S, Fujisawa K, Fukunaga M, Araki E; Kumamoto Insulin Degludec Observational (KIDUNA) Study Group: A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study). J Diabetes Invest 7(5):703-710, 2016.
  • Hanatani S, Motoshima H, Takaki Y, Kawasaki S, Igata M, Matsumura T, Kondo T, Senokuchi T, Ishii N, Kawashima J, Kukidome D, Shimoda S, Nishikawa T, Araki E. Acetate alters expression of genes involved in beige adipogenesis in 3T3-L1 cells and obese KK-Ay mice. J Clin Biochem Nutr 59(3):207-214, 2016.
  • Sada K, Nishikawa T, Kukidome D, Yoshinaga T, Kajihara N, Sonoda K, Senokuchi T, Motoshima H, Matsumura T, Araki E: Hyperglycemia induces cellular hypoxia through production of mitochondrial ROS followed by suppression of aquaporin-1. PLOS One 11(7):e0158619, 2016.
  • Inagaki N, Araki E, Oura T, Matsui A, Takeuchi M, Tanizawa Y: The combination of dulaglutide and biguanide reduced body weight in Japanese patients with type 2 diabetes. Diabetes Obes Metab 18(12):1279-1282, 2016.
  • Nishikawa T, Araki E: Involvement of advanced glycation end-products in ‘hyperglycemic memory’. J Diabetes Investig 7(3):297-299, 2016.
  • Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart JC, Kodama T; K-877-04 Study Group: Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis 249:36-43, 2016.
  • Kukidome D, Nishikawa T, Sato M, Igata M, Kawashima J, Shimoda S, Matsui K, Obayashi K, Ando Y, Araki E: Measurement of small fibre pain threshold values for the early detection of diabetic polyneuropathy. Diabet Med 33(1):62-69, 2016.
  • Kondo T, Goto R, Ono K, Kitano S, Suico MA, Sato M, Igata M, Kawashima J, Motoshima H, Matsumura T, Kai H, Araki E: Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial. Sci Rep 6:35690, 2016.
  • Araki E, Haneda M, Kasuga M, Nishikawa T, Kondo T, Ueki K, Kadowaki T: New glysemic targets for patients with diabetes from the Japan Diabetes Society. Diabetology International 7(4):327-330, 2016.

2015年

  • Shimoda S, Okubo M, Koga K, Sekigami T, Kawashima J, Kukidome D, Igata M, Ishii N, Shimakawa A, Matsumura T, Motoshima H, Furukawa N, Nishida K, Araki E. Insulin requirement profiles in Japanese hospitalized subjects with type 2 diabetes treated with basal-bolus insulin therapy. Endocr J 62:209-216, 2015.
  • Fukuda K, Matsumura T, Senokuchi T, Ishii N, Kinoshita H, Yamada S, Murakami S, Nakao S, Motoshima H, Kondo T, Kukidome D, Kawasaki S, Kawada T, Nishikawa T, Araki E. Statins meditate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor-γ activation. Biochem Biophys Res Commun 457:23-30, 2015.
  • Nishikawa T, Brownlee M, Araki E. Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy. J Diabetes Invest 6:137-139, 2015
  • Kukidome D, Nishikawa T, Sato M, Igata M, Kawashima J, Shimoda S, Matsui K, Obayashi K, Ando Y, Araki E. Measurement of small fibre pain threshold values for the early detection of diabetic polyneuropathy. Diabetic Medicine 33(1):62-69, 2015.
  • Oyama K, Taniguchi J, Goto R, Matsui K. Remitting seronegative symmetrical synovitis with pitting edema syndrome in individuals with type 2 diabetes mellitus or impaired glucose tolerance. Diabetes Res Clin Pract. 110(1):e5-8, 2015.
  • Araki E, Tanizawa Y, Tanaka Y, Taniguchi A, Koiwai K, Kim G, Salsali A, Woerle H.J, Broed U.C. Long-term treatment with empagliflozin as add-on to oral anti-diabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obesity & Metabolism 17(7): 665-674, 2015
  • Kawashima J, Naoe H, Sasaki Y, Araki E. A rare case showing subacute thyroiditis-like symptoms with amyloid goiter after ani-tumor necrosis factor therapy. Endocrinology, Diabetes & Metabolism 2015, in press
  • Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Efficacy and safety of once weekly Efficacy and safety of once weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once daily insulin glargine in Japanese patients with type 2 diabetes: a randomised, open-label, phase 3, non-inferiority study. Diabetes Obesity & Metabolism 17(10):994-1002, 2015.
  • Araki E, Kondo T, Kai H. Cellular stress response pathways and diabetes mellitus. Diabetol Int 6: 239-242, 2015.

2014年

  • Uchimura K, Hayata M, Mizumoto T, Miyasato Y, Kakizoe Y, Morinaga J, Onoue T, Yamazoe R, Ueda M, Adachi M, Miyoshi T, Shiraishi N, Ogawa W, Fukuda K, Kondo T, Matsumura T, Araki E, Tomita K, Kitamura K. The serine protease prostasin regulates hepatic insulin sensitivity by modulating TLR4 signalling. Nat Commun 5;3428, 2014.
  • Takahashi T, Harada M, Kikuno T, Ujihara M, Sadamitsu D, Manabe Y, Yasaka M, Takayama H, Kobori S, Araki E: Prevalence of metabolic syndrome in stroke patients: a prospective multicenter study in Japan. Acute Med Surg 1:17-22, 2014.
  • Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K, Iwamoto Y, Watada H, Ohtsuka W, Watanabe D, Suganami H; for the Tofogliflozin 004 and 005 Study group. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother 15:749-766, 2014.
  • Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 13(1):65, 2014.
  • Yoshizawa T, Karim MF, Sato Y, Senokuchi T, Miyata K, Fukuda T, Go C, Tasaki M, Uchimura K, Kadomatsu T, Tian Z, Smolka C, Sawa T, Takeya M, Tomizawa K, Ando Y, Araki E, Akaike T, Braun T, Oike Y, Bober E, Yamagata K. SIRT7 controls hepatic lipid metabolism by regulating the ubiquitin-proteasome pathway. Cell Metab 19(4):712-21, 2014.
  • Shimoda S, Iwashita S, Sekigami T, Furukawa N, Matsuo Y, Ichimori S, Goto R, Maeda T, Watanabe E, Kondo T, Matsumura T, Motoshima H, Nishida K, Araki E. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. J Diabetes Investig 5:320-6, 2014.
  • Kondo T, Ono K, Kitano S, Matsuyama R, Goto R, Suico MA, Kawasaki S, Igata M, Kawashima J, Motoshima H, Matsumura T, Kai H, Araki E. Mild electrical stimulation with heat shock reduces visceral adiposity and improves metabolic abnormalities in subjects with metabolic syndrome or type 2 diabetes: Randomized crossover trials. EBioMedicine 1:80-89, 2014.
  • Kondo T, Motoshima H, Igata M, Kawashima J, Matsumura T, Kai H, Araki E. The role of heat shock response in insulin resistance and diabetes. Diabetes Metab J 38:100-6, 2014.
  • Matsuyama S, Moriuchi M, Suico MA, Yano S, Morino-Koga S, Shuto T, Yamanaka K, Kondo T, Araki E, Kai H. Mild electrical stimulation increases stress resistance and suppresses fat accumulation via activation of LKB1-AMPK signaling pathway in C. elegans. PLoS One 9:e114690, 2014.
  • Marume K, Arima Y, Igata M, Nishikawa T, Yamamoto E, Yamamuro M, Tsujita K, Tanaka T, Kaikita K, Hokimoto S, Ogawa H. Prolonged hyponatremia due to hypopituitarism in a patient with non-ST-elevation myocardial infarction. Journal of Cardiology Cases 10: 226-230, 2014.
  • Ueno-Shuto K, Kato K, Tasaki Y, Sato M, Sato K, Uchida Y, Sakai H, Ono T, Suico MA, Mitsutake K, Tokutomi N, Kai H, Shuto T. Lipopolysaccharide decreases single immunoglobulin interleukin-1 receptor-related molecule (SIGIRR) expression by suppressing Sp1 via TLR4-p38 pathway in monocytes and neutrophils. J Biol Chem 289:18097-18109, 2014.

<< 1 >>


【受賞】代謝内科学業績

業績 – 受賞

受賞業績については随時更新予定

<< 1 >>